<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038194</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-271</org_study_id>
    <nct_id>NCT00038194</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer</brief_title>
  <official_title>Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest safe dose of docetaxel in&#xD;
      combination with Gleevec (imatinib mesylate) that can be given to men with advanced&#xD;
      androgen-independent metastatic prostate cancer that involves bone. Docetaxel is a commercial&#xD;
      chemotherapy which interferes with the cancer cell ability to divide and grow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        1. To define the maximum tolerated dose of weekly docetaxel in combination with fixed-dose&#xD;
           oral STI571 in adult men with metastatic androgen-independent prostate cancer (AIPC).&#xD;
&#xD;
        2. To determine the qualitative and quantitative toxicity of the combination of oral STI571&#xD;
           and docetaxel.&#xD;
&#xD;
        3. Evaluate PSA modulation with STI571 alone at thirty days in patients with AIPC.&#xD;
&#xD;
        4. Obtain a preliminary estimate of the response rate in AIPC to the combination of STI571&#xD;
           and docetaxel.&#xD;
&#xD;
        5. Obtain tissue for correlative science studies (these are optional studies).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Imatinib + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <arm_group_label>Imatinib + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Imatinib + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Patients with histologic proof of adenocarcinoma of the prostate and must have&#xD;
             progressed on conventional hormonal therapy.&#xD;
&#xD;
          -  Patients must have bone metastases which can be demonstrated by bone scans. Lytic bone&#xD;
             lesions should be considered for biopsy if there is a clinical suspicion of histologic&#xD;
             conversion to small cell carcinoma.&#xD;
&#xD;
          -  Patients must have evidence of progression of disease. PSA- progression is defined as&#xD;
             2 consecutive increments in PSA (an absolute change of at least 1ng/mL) over 4 weeks.&#xD;
             An increase by 25% of the product of bidimensional disease qualifies as progression.&#xD;
             An increase in the number of metastatic lesions on bone scan qualifies as progression.&#xD;
&#xD;
          -  All patients must have a minimum PSA of 1ng/ml.&#xD;
&#xD;
          -  Patients on antiandrogens should be discontinued from flutamide or nilutamide for at&#xD;
             least 4 weeks and bicalutamide for 8 weeks. If progression is documented as below&#xD;
             prior to this time interval, patients are eligible.&#xD;
&#xD;
          -  Patients must have a performance status of &lt; 2 (ECOG).&#xD;
&#xD;
          -  Patients must have an expected survival from cancer or co-morbidity of at least three&#xD;
             months.&#xD;
&#xD;
          -  Patients may receive no concurrent chemotherapy, immunotherapy or ketoconazole.&#xD;
&#xD;
          -  Patients should not have received prior chemotherapy or radiation within the last 30&#xD;
             days and no Strontium or Samarium within the last 90 days.&#xD;
&#xD;
          -  Patients must have castrate serum testosterone levels (&lt; 30ng/dl). For patients who&#xD;
             are medically castrated, luteinizing hormone releasing hormone analog must continue to&#xD;
             maintain testicular suppression.&#xD;
&#xD;
          -  Patients must have adequate bone marrow function defined as an absolute peripheral&#xD;
             granulocyte count of &gt; 1,500/mm3 and platelet count of &gt; 100,000/mm3.&#xD;
&#xD;
          -  Patients should have adequate hepatic function defined with a bilirubin of &lt; 1.5 mg/dl&#xD;
             and AST/ALT &lt; 2X the upper limits of normal.&#xD;
&#xD;
          -  Patients should have adequate renal function defined as serum creatinine clearance &gt;&#xD;
             40 cc/min (measured or calculated by Cockcroft and Gault formula) or serum creatinine&#xD;
             &lt; 1.5 X upper limit of normal.&#xD;
&#xD;
          -  Fully recovered from any previous surgery (at least 4 weeks since major surgery.&#xD;
&#xD;
          -  Patients must sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of this study, in keeping with the policies of the institution.&#xD;
             The only approved consent is attached to this protocol.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Patients with severe intercurrent infection.&#xD;
&#xD;
          -  Patients whose tumors contain small cell or sarcomatoid elements.&#xD;
&#xD;
          -  Patients with NYHA Class III/IV CHF, unstable angina or MI in the last 6 months or&#xD;
             evidence of active myocardial ischemia on ECG.&#xD;
&#xD;
          -  CNS metastases that are uncontrolled.&#xD;
&#xD;
          -  Prior hypersensitivity or dose-limiting toxicity with docetaxel.&#xD;
&#xD;
          -  Oxygen-dependent lung disease&#xD;
&#xD;
          -  Contraindications to corticosteroids.&#xD;
&#xD;
          -  Uncontrolled severe hypertension or uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Second malignancies (except non-melanoma skin cancer) unless disease-free for 3 years.&#xD;
&#xD;
          -  Overt psychosis or mental disability or otherwise incompetent to give informed&#xD;
             consent.&#xD;
&#xD;
          -  Patients with a history of non-compliance with medical regimens or who are considered&#xD;
             potentially unreliable.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>U.T. M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 29, 2002</study_first_submitted>
  <study_first_submitted_qc>May 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2002</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>bone metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

